Objectives: This trial examined the efficacy of a stress management program in reducing neuroimaging markers of multiple sclerosis (MS) disease activity.
Accumulating evidence suggests an association between stress and disease activity in multiple sclerosis (MS). 1 Stressful life events have also been shown to precede new gadolinium-enhancing (Gdϩ) MRI brain lesions, a more objective measure of disease activity, by approximately 4 -8 weeks. 2 Several studies have indicated that more adaptive coping moderates the effect of stress on the development of new Gdϩ lesions 3 and is associated with fewer exacerbations. 4 Cognitive behavioral stress management therapies (SMTs) teach coping skills that are aimed at enhancing a patient's ability to prevent stressful events from occurring and improving the capacity to manage their responses to those stressful events that do arise.
The primary aim of this multicenter randomized controlled clinical trial (RCT) was to examine the efficacy of a well-validated SMT for MS (SMT-MS) 5 in reducing the occurrence of new Gdϩ lesions and new or enlarging T2-weighted lesions. Gdϩ MRI is a marker of the opening of the blood-brain barrier and is typically used as a primary endpoint in phase II trials because of its high sensitivity to ongoing MS disease activity and its association with clinical exacerbation. 6 T2-weighted MRI is also commonly used in phase II trials to identify more permanent lesions.
METHODS Study design.
This was a 48-week phase II randomized, multicenter, controlled, evaluator-blind, two-arm trial of cognitive-behavioral stress management therapy for MS (SMT-MS) 5 ,7 compared to a wait-list control. Treatment was provided over 24 weeks followed by a 24-week post-treatment follow-up period. Participants were enrolled at MS specialty clinics at 3 sites in the United States (University of California San Francisco [UCSF]; Evergreen Hospital Medical Center, Seattle, Washington; and the Feinberg School of Medicine at Northwestern University, Chicago, Illinois) and through local chapters of the National MS Society. It was hypothesized that participants randomized to SMT-MS would show significantly fewer new Gdϩ and T2 lesions, compared to those in the control condition during the treatment period, and that improvements would be sustained over the 24-week follow-up period. This study provides Class I evidence for the primary hypotheses.
Standard protocol approvals, registrations, and patient consents. This trial was approved by institutional review boards at each institution and all participants were consented accordingly. A Data Safety Monitoring Board monitored the conduct of the study and safety of participants. The trial was registered with ClinicalTrials.gov, number NCT00147446.
Randomization. An independent statistician, blind to initial assessment to ensure allocation concealment, used computer generated randomization with a 1:1 ratio, stratified by site, and block size of 4 within each site. Treatment assignment was communicated to the patient by the central study coordinator to prevent unblinding of local evaluators.
Participant inclusion criteria. Eligible participants were diagnosed with MS according to the MacDonald criteria 8 and had documented evidence of clinical exacerbation or at least 1 Gdϩ MRI brain lesion within 12 months prior to enrollment. The qualifying exacerbation or Gdϩ lesion had to have occurred at least 1 month after initiation of an interferon drug or 6 months after initiation of glatiramer acetate. All participants were at least 18 years of age, were able to speak and read English, and had a score of 0 -6.5 on the Expanded Disability Status Scale (EDSS). 9 Participants were excluded if they had received corticosteroids in the past 28 days, were treated with a cytotoxic agent or natalizumab, had other autoimmune or endocrine disorders, were unable to undergo Gdϩ MRI, were pregnant or planning pregnancy, were diagnosed using the Mini International Neuropsychiatric Interview 10 with any severe psychiatric disorder (e.g., psychotic disorders, bipolar disorder), or were currently receiving or planning to begin psychotherapy. Participants were also excluded if they met criteria for dementia, defined consistent with previous trials 11 as being below the fifth percentile on 3 or more of the following: Symbol Digit Modalities, Digit Span, Hopkins Verbal Learning Test, Controlled Word Association Test, Similarities, and the 10/36 test.
Treatment. Eligible participants were randomized to receive either the active treatment, SMT-MS, or a wait-list control condition in addition to their current disease-modifying therapy (DMT) regimen.
SMT-MS is a manualized, validated, published stress management program designed for patients with MS. 5, 7 Participants met with a therapist for 16 individual 50-minute sessions conducted over 20 -24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction. To avoid potential confounds with pharmacologic interventions, therapists were prohibited from discussing the DMTs or psychotropic medications and instructed to refer participants back to the prescribing physician if patients had questions regarding their treatments.
Therapists were 7 PhD level licensed psychologists with more than 3 years postdoctoral experience and 1 licensed social worker who had more than 30 years experience with cognitive behavioral therapy. Treating therapists received 1 day of training in the treatment model and weekly supervision for the first year, which could be reduced to once every 2-3 weeks thereafter, as determined by the supervising psychologists. The supervision team included 3 senior psychologists, including the first author. All sessions were audiotaped. Audiotapes were randomly selected and rated by a supervising psychologist using the Cognitive Therapy Scale 12 to ensure treatment fidelity and for supervision. Wait list control provided treatment as usual for the first 10ϩ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluations that were not contaminated by the workshop.
Assessment. Masking. All clinical evaluators and technicians
were blinded to treatment assignment.
MRI scanning and analysis. MRI of the brain (T2/T1-weighted images) with injection of a single dose of Gd was performed according to a standardized protocol using a 3.0-Tesla magnet at each site. MRI was performed during baseline and at weeks 8, 16, 24 32, 40, and 48. "Dummy" scans and quality control were performed at each site prior to first subject enrollment. A central MRI reading unit (UCSF, San Francisco) evaluated MRI scans for quality and measurement of the study endpoints according to standardized postprocessing protocols.
The primary outcome was the cumulative number of Gdϩ lesions during the active treatment period (weeks 8, 16, and 24). Secondary outcomes included cumulative number of new and enlarging T2 lesions, number of participants free of Gdϩ and of new T2 lesions, percent brain volume change over 48 weeks from volumetric high-resolution (1 mm 3 , 124 slices) T1-weighted gradient-echo images using SIENA, 13 and change in T2 volume from baseline to week 48. T2 lesion volume analysis was performed on all scans using a semiautomated thresholding method and manual editing with simultaneous view access to both T2 and proton density-weighted slices. An automated coregistration procedure was applied on subsequent time points onto each subject baseline scan.
Stress outcomes. The occurrence of negative stressful events was measured using the Life Events Scale (LES), 14 administered monthly by telephone interview. Assessment of subjective perceived stress was measured by monthly self-report using the Brief Inventory of Perceived Stress (BIPS).
Clinical neurology outcomes. Exacerbations were verified by an evaluating MS physician or trained registered nurse using the same definition implemented in recent DMT trials. 16 Participants were also evaluated clinically at 16-week intervals to document their EDSS and adverse events. Patients with confirmed exacerbations were referred to their physicians for treatment.
Statistical analyses.
The power analysis as originally proposed was based on preliminary data derived from monthly MRI scans. 2 Planning for 6 monthly scans during the treatment period, we expected 50% of control participants to have Gdϩ lesions on the first scan, dropping to 40% by 24 weeks. Using an intent-to-treat (ITT) analysis, ␣ of 0.05, power of 0.80, 2-tailed testing, and a 10% reduction in the occurrence of Gdϩ lesions in the treated arm compared to the control group, we required 60 participants in each group for a total sample size of approximately 120 participants. Funding cuts and other feasibility constraints led to design changes that included reducing the number of scans to every other month. Consequently, using a Wilcoxon test to detect differences in cumulative lesion counts during the treatment period, taking into account missing values, the current study had 59% power to detect a significant difference in cumulative Gdϩ lesions.
Data were analyzed using SAS (v. 9.2 SAS Corporation, Cary, NC). Demographics and clinical characteristics at baseline between treatment groups were compared using t test for continuous data and 2 for categorical variables.
The ITT sample included all participants who were randomized. To calculate the primary endpoint it was necessary to impute missing Gdϩ lesions at each timepoint. Since new and enlarging T2 lesions were measured since the previous MRI, it was only necessary to impute missing T2 lesions for missing values at week 24. Nonparametric multiple imputation methods were used to impute missing lesion values. 17 Twenty imputations were made for each missing value.
Because small numbers of patients can have unusually large numbers of lesions, nonparametrics are typically used to avoid the influence of outliers. Cumulative lesion counts for both Gdϩ and T2 lesions were compared between treatment groups using a Wilcoxon test on each imputed dataset. Test results across the imputed datasets were combined using multiple imputation combining rules described by Li et al. 18 Analyses were conducted during the treatment phase and post-treatment follow-up. Between-group comparisons of the proportion of patients free of lesions were performed using logistic regression, with test statistics combined across the imputed datasets. 18 Mixed-effects repeated measures model with random subject-specific intercepts was used to detect treatment and time ϫ treatment effects on both LES and BIPS. Percent brain volume changes and the rate of confirmed exacerbation were compared between treatment groups using t test and 2 , respectively. The same method of comparing cumulative lesions counts was used to check the relationship between MRI lesion activity and DMT. 
RESULTS
ful. There were no significant differences across treatment groups in any other demographic or disease variables ( ps Ͼ 0.
24).
Treatment adherence. Of the 60 participants assigned to SMT-MS, 50 (83.3%) were classified as treatment completers (12 or more sessions).
Lost to follow-up. A CONSORT diagram showing the flow of participants through each stage of this randomized controlled trial is displayed in figure 1 . The lost to follow-up rate was not significantly different across treatment arms ( 2 ϭ 3.20, p ϭ 0.07). The lost to follow-up rate was not significantly related to any baseline demographic or clinical variables (all ps Ͼ 0.31).
Primary endpoint and secondary MRI outcomes:
Treatment period. Treatment with SMT-MS produced a significant reduction in cumulative Gdϩ lesions compared to the control condition during the treatment period (table 2; p ϭ 0.04). The median (value at the 50th percentile) number of new Gdϩ lesions was 0 in both groups, given most participants had no new Gdϩ lesions during the 24-week treatment period, but the difference was apparent at the upper end of the distributions. Using the upper 75th percentile, participants in SMT-MS had 0 lesions, compared with 1 lesion in the control condition. As shown in figure 2 , significantly greater numbers of participants receiving SMT-MS remained free of Gdϩ lesions during the treatment, compared to those receiving the control condition (76.8% vs 54.7%, OR ϭ 2.77; 95% CI ϭ 1.17-6.55; p ϭ 0.02). The absolute risk reduction was 22.2% and the number needed to treat (NNT) ϭ 5.
Participants receiving SMT-MS showed a significant reduction in cumulative new T2 lesions, compared to those receiving the control condition (median ϭ 1 vs 0; 75th percentile ϭ 3 vs 1; p ϭ 0.005). Similarly, figure 2 shows that significantly greater numbers of participants receiving SMT-MS remained free of new T2 lesions, compared to control condition participants (69.5% vs 42.7%, OR ϭ 3.07; 95% CI ϭ 1.38 -6.81; p ϭ 0.006). As T2 imaging is more sensitive than Gdϩ to events over an 8-week interval, figure 3 also displays the percentage of patients free of T2 lesions at each time point throughout the entire study. The absolute risk reduction was 26.8% and NNT ϭ 4.
MRI outcomes: Post-treatment. There were no statistically significant differences across treatment arms in cumulative Gdϩ lesions or new T2 lesions on any analyses during the post-treatment follow-up weeks 32-48 ( ps Ͼ 0.45). The difference in the number of participants remaining free of Gdϩ lesions during the post-treatment follow-up remained marginally significant (60.6% vs 43.0%, p ϭ 0.08), but there was no significant effect for remaining free of T2 lesions through week 48 ( p ϭ 0.11).
Change in T2 lesion volume and atrophy. Because one would not expect to see changes in T2 lesion volume or atrophy over periods less than 48 weeks, these were examined over the entire study period. There was no significant difference in change in T2 lesion volume across treatment arms ( p ϭ 0.37). However, there was significantly less percent brain volume change among participants receiving SMT-MS (mean loss Ϫ0.11%) compared to those receiving the control condition (mean loss Ϫ0.43%; p ϭ 0.01). Interferon-␤ 1a (Avonex) 100 8 (14) 10 (16) 18 (15) Interferon-␤ 1b (Betaseron) 101 5 (9) 5 (8) 10 (9) Interferon-␤ 1a (Rebif) 108 25 (44) 23 (38) 48 (41) Glatiramer acetate 103 8 (14) 9 (15) 17 (14) None 11 (19) 14 (23) 25 ( Clinical neurology outcomes. There were no significant differences in the number of confirmed exacerbations, either from baseline to week 24 (22 in both arms; p ϭ 0.84) or from week 24 through week 48 (15 in SMT vs 18 in control; p ϭ 0.40). Similarly, there were no differences in EDSS over the trial period ( p ϭ 0.15).
Adverse events. There were no serious adverse events associated with SMT-MS.
DISCUSSION This RCT found significantly fewer new Gdϩ brain lesions and new or enlarging T2 lesions among participants treated with SMT-MS, compared to the control group, indicating that SMT-MS can reduce not only the extent of bloodbrain barrier opening, but also the accumulation of fixed lesions. These outcomes were not influenced by DMT status, and were achieved with no adverse side effects. The effect sizes were similar to other recent phase II trials of new pharmacotherapies.
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These findings are consistent with epidemiologic studies showing that stressful life events increase the risk of new Gdϩ MRI lesions 2 and MS exacerbations 20 and provide more conclusive evidence of the link between stress and MRI activity, given that the RCT design eliminates potential biases that are inherent in epidemiologic studies. Our results are especially encouraging since we selected our participants for higher disease activity.
The differences in outcomes between treatment groups during the treatment period were not sustained during the post-treatment follow-up period. The effect on atrophy over 48 weeks, while worthy of further investigation, was unexpected and therefore cannot be interpreted. There are at least 2 possible explanations why neuroimaging outcomes were not maintained. It is possible that participants learned and implemented new coping skills during the trial, but were unable to sustain these new behaviors once the support of active treatment ended. Difficulty maintaining behavior change after treatment cessation is a problem encountered by many behavioral interventions 21 and can also occur among patients with MS. 22 Alternatively, it may be that nonspecific treatment factors such as patient expectancies or the experience of a supportive relationship were responsible for the changes in Gdϩ lesions. Both of these have been shown to affect immune function. 23, 24 In either case, these data suggest that maintaining the effects over longer periods of time may require more sustained intervention. However, long-term standard behavioral intervention can be burdensome for patients who must make weekly office visits. More accessible models of providing care using telecommunications media may make sustained interventions accessible to patients. Indeed, SMT-MS has been shown to be effective when delivered via telephone 25 and a growing literature indicates that Internet and smartphone interventions can be effective. 26 A number of the hypothesized pathways have been described by which stress or SMT-MS may affect MS disease activity, 27, 28 most notably via the number and function of glucocorticoid receptors on immune cells. Future analyses of data from this trial will examine secondary hypotheses regarding such biological and psychosocial pathways. Understanding these pathways may allow refinements to the intervention that can more specifically target factors affecting MS pathogenic processes.
There are limitations in our study that should be considered. First, this trial was not powered to detect clinical outcomes, and indeed, there was no evidence that SMT-MS reduced clinical outcomes. Second, while differences in the lost to follow-up rate did not differ significantly across treatment arms, they did differ marginally. The lost to follow-up rate of 22% in SMT-MS is comparable to many other trials of behavioral interventions, 29 while the loss of 10% of participants in the wait list control condition is consistent with rates seen in pharmaceutical trials in MS trials more generally. 16, 30 There was no evidence that dropout was related to demographic or diseaserelated variables and our statistical analyses attempted to control for the lost to follow-up using imputation. However, it is possible that there were other unmeasured variables that that could have introduced bias. While the 22% attrition rate is not unexpected, delivering care via telephone or other media (videoconferencing, Internet) can improve adherence with similar levels of efficacy. Abbreviations: Gdϩ ϭ gadolinium-enhancing; SMT-MS ϭ stress management therapy for multiple sclerosis; WLC ϭ wait list control.
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Finally, the wait list control did not control for nonspecific factors such as attention. An examination of the mediating factors in SMT-MS that contribute to the outcomes is planned for a separate publication. While SMT-MS has repeatedly been demonstrated to produce many benefits, including improved mood, fatigue, and quality of life among people with MS, 25, [32] [33] [34] we caution that it is premature to make specific clinical recommendations regarding the use of SMT-MS to manage MS disease-related activity. Future work should identify, refine, and optimize the active ingredients in this behavioral intervention. Clinical outcomes will be important to assess in the future in phase III trials.
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Figure 2
Percent of participants free of gadolinium-enhancing (Gd؉) and T2 lesions by treatment group during 24-week treatment period SMT-MS ϭ stress management therapy for multiple sclerosis. SMT-MS ϭ stress management therapy for multiple sclerosis.
